Tetsuo Shimizu

11PUBLICATIONS
9CO-AUTHORS
Innate immunityPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 03, 2026
Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study.

Ippei Miyamoto, Tetsuo Shimizu, Mizuki Hanamura

|Jun 28, 2025
Impact of response on survival according to type of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.

Tetsuo Shimizu, Masayuki Nomoto, Yoshiko Nakagawa

|Feb 04, 2025
The Impact of Immune-Related Adverse Event Severity on Prognosis in Elderly Patients With Nonsmall-Cell Lung Cancer in First-Line Immune Checkpoint Inhibitor Treatment.

Ippei Miyamoto, Tetsuo Shimizu, Mizuki Hanamura

|Jun 20, 2024
Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer.

Hiroaki Kodama, Haruyasu Murakami, Nobuaki Mamesaya

|Dec 14, 2023
Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants.

Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani

|May 09, 2023
Anti-synthetase syndrome-associated interstitial lung disease possibly caused by atezolizumab in a patient with lung adenocarcinoma: a case report.

Ippei Miyamoto, Tetsuo Shimizu, Ryo Kusahana

Pageof 2

Frequent Collaborators

5 joint publications

Yoshiko Nakagawa

2 joint publications

Yuko Iida

2 joint publications

Tateaki Naito

2 joint publications

Toshiaki Takahashi